Business Context and Reporting Period
This Form 6-K filing by I-Mab (not Novabridge Biosciences) covers the month of September 2024, with the report dated September 23, 2024. The filing primarily addresses a change in the composition of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate governance and does not contain financial statements or performance metrics.
Material Changes
- Director Resignation: Mr. Shuai Chen resigned from the Board of Directors effective September 18, 2024, due to personal reasons. The filing states this was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Mr. Lielie Zhang was appointed as an independent member of the Board and the Audit Committee, effective September 18, 2024.
Management Commentary and Risks
Mr. Lielie Zhang brings extensive experience in corporate and financial management, including roles as an Investment Director at Hony Capital and a board member at Shanghai Chengtou Holding Co., Ltd. He previously worked in investment banking at Pudong Development Bank for over ten years. Mr. Zhang will not receive compensation for his service as a director or Audit Committee member. There are no related-party transactions involving Mr. Zhang requiring disclosure.
Key Facts for Investor Verification
- Confirm the effective date of the board changes (September 18, 2024).
- Verify Mr. Lielie Zhang's background and independence status as disclosed.
- Note that the resignation of Mr. Shuai Chen was explicitly stated as not resulting from any disagreement with the Company.
- Understand that this filing contains no financial performance data for the period.